SABS
SAB Biotherapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.28 EPS
$3.80
▼ -1.81%$3.80▲ +115.91%
over 1Y
L $1.69EODHDH $4.59
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.8%
1W-3.3%
1M+5.6%
3M-1.3%
YTD+0.8%
1Y+115.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.14x); but revenue fell -100.0% YoY.
Revenue (FY2025) $0.00 · FY2025
SAB Biotherapeutics, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and 8.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $60.9M | $23.9M | $2.24M | $1.32M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.4M | -$28.9M | -$38.1M | -$42.9M | -$49.0M |
| Net income | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
| Diluted EPS | -$0.63 | -$4.31 | -$7.64 | -$3.68 | -$0.79 |
| Net margin | -28.2% | -78.4% | -1884.5% | -2579.0% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$183M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield6.9%
FCF yield-23.6%
Quality & risk
ROIC (est.)-25.5%
Free cash flow-$45.7M
Total debt—
Net cash$10.5M
Altman Z-Score4.24 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+448.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-252026-06-26open ↗8-KPeriod ending 2026-06-182026-06-18open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-04-282026-05-04open ↗SCHEDULE 13GFiling2026-05-01open ↗DEF 14APeriod ending 2026-06-182026-04-30open ↗8-KPeriod ending 2026-04-222026-04-22open ↗S-8Filing2026-03-31open ↗4Period ending 2026-03-242026-03-25open ↗
Frequently asked
- Is SAB Biotherapeutics, Inc. (SABS) a buy?
- SABS currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.14x); but revenue fell -100.0% YoY.
- What is SAB Biotherapeutics, Inc.'s quality score?
- SABS scores 68.53846153846153/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001833214, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:56:32 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.